MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Amphastar Pharmaceuticals Accounts Receivables 2011-2026 | AMPH
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 144 M | 136 M | 115 M | 88.8 M | 78.8 M | 66 M | 45.4 M | 52.2 M | 36 M | 26.8 M | 33.2 M | 22.9 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 144 M | 22.9 M | 70.4 M |
Quarterly Accounts Receivables Amphastar Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 147 M | 133 M | 145 M | 136 M | 140 M | 131 M | - | 115 M | 119 M | - | 101 M | 88.8 M | - | 80.8 M | 73.2 M | 78.8 M | 78.1 M | 67.9 M | 77.9 M | 66 M | 66 M | 66 M | 66 M | 45.4 M | 45.4 M | 45.4 M | 45.4 M | 52.2 M | 52.2 M | 52.2 M | 52.2 M | 36 M | 36 M | 36 M | 36 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 22.9 M | 22.9 M | 22.9 M | 22.9 M | 24.6 M | 24.6 M | 24.6 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 147 M | 22.9 M | 62 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
778 M | $ 334.86 | -1.34 % | $ 43.9 B | USA |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
Esperion Therapeutics
ESPR
|
140 M | $ 2.08 | 1.22 % | $ 432 M | USA |
 |
Aptinyx
APTX
|
257 K | - | -39.0 % | $ 4.57 M | USA |
 |
Genmab A/S
GMAB
|
34 M | $ 29.26 | 0.67 % | $ 18.8 B |  Danmark |
 |
GT Biopharma
GTBP
|
40 K | $ 0.38 | -1.83 % | $ 2.1 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
96.8 M | $ 29.22 | -0.24 % | $ 1.68 B | USA |
 |
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M | USA |
 |
ImmuCell Corporation
ICCC
|
3.42 M | $ 7.64 | -1.18 % | $ 69 M | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
Akebia Therapeutics
AKBA
|
47 M | $ 1.54 | -1.23 % | $ 396 M | USA |
 |
Aquestive Therapeutics
AQST
|
17.8 M | $ 4.19 | 1.07 % | $ 448 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
146 M | $ 24.26 | -3.31 % | $ 3.09 B | USA |
 |
Incyte Corporation
INCY
|
1.02 B | $ 97.7 | 0.01 % | $ 19.1 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
312 K | - | -2.5 % | $ 5.88 M | USA |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
56.9 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
24 M | $ 1.48 | -0.34 % | $ 394 M |  Britain |
 |
BeiGene, Ltd.
BGNE
|
865 M | - | 0.49 % | $ 251 B |  Cayman-islands |